Latest News Story Headlines
2024 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter.
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug.
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Jun 24, 2024
Calendar & Upcoming Events
Webinar: The power of daily rituals
Webinar Session, Wednesday, November 6th, 2024 at 6 PM (ET)
Webinar: Understanding your blood work
Webinar Session, Wednesday, November 13th, 2024 at 6 PM (ET)
Sign Up for the Latest Updates
Get news from Amyloidosis Foundation
in your inbox
By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.